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Background
Radical prostatectomy (RP) is frequently responsible
for erectile dysfunction (ED). Post-RP patients often
show insufficient response or treatment failures to
PDE5 inhibitor therapy. This study was undertaken to
evaluate the acute effects of the soluble guanylate
cyclase (sGC) stimulator, BAY 60-4552 and vardenafil
administered alone or in combination on erectile
responses to electrical stimulation of the cavernous
nerve (ES-CN) in rats with cavernous nerve (CN)
crush injury-induced ED.
Design and methods
Male Sprague-Dawley rats underwent laparotomy (sham,
n=10) or bilateral CN crush injury (n=57). After 3
weeks of recovery, erectile function was evaluated in
urethane-anesthetized rats following ES-CN at different
frequencies. The acute effects of intravenous (iv) injec-
tion of vehicle, vardenafil 0.03 mg/kg, BAY 60-4552 0.03
mg/kg or 0.3 mg/kg, or a BAY 60-4552 0.03 mg/kg +
vardenafil 0.03 mg/kg combination were evaluated in
CN crushed rats.
Results
Bilateral CN crush injury followed by a 3-week recovery
period decreased erectile responses to ES-CN by about
50%. In CN crushed rats, both iv vardenafil 0.03 mg/kg
and BAY 60-4552 at the tested dosings (0.03 or 0.3 mg/
kg) increased erectile responses to ES-CN to the same
extent: ΔICP/MAP at 10Hz ES-CN was 20.9± 1.3 %
after iv vehicle, 25.3± 3.3 % (P<0.001) after iv vardenafil,
and 26.3± 4.9 % and 26.6± 5.2 % after BAY 60-4552
0.03 mg/kg (P<0.01) and 0.3 mg/kg (P<0.001) respec-
tively. The combined iv administration of vardenafil and
BAY 60-4552 in CN crushed rats exerted additive effects
and totally restored erectile responses to ES-CN equiva-
lent to sham rats (ΔICP/MAP at 10Hz ES-CN : 34.0±
4.4 % after BAY 60-4552/vardenafil combination vs 39.2
± 3.7 % in sham rats, ns).
Conclusion
The present study supports the concept that the com-
bined administration of a sGC stimulator, BAY 60-4552
and vardenafil provides additive beneficial effects. Thus
this combination could become a novel treatment
option in ED patients with cavernous nerve injury show-
ing insufficient response or treatment failures to PDE5
inhibitors.
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